Take Homes in Lung Cancer

Take Homes in Lung Cancer

Source: Healio Interview
Disclosures: Gandara reports receiving institutional research grants from Amgen, AstraZeneca, Genentech and Merck; and serving as a consultant or on advisory boards for AstraZeneca (institutional), Roche-Genentech (institutional), Guardant Health (institutional), Inivata, IO Biotech (institutional), Lilly, Merck, Novartis and Oncocyte (institutional)
August 16, 2021
1 min watch
Save

VIDEO: ILCC serves as ‘think tank’ for lung cancer experts

Source: Healio Interview
Disclosures: Gandara reports receiving institutional research grants from Amgen, AstraZeneca, Genentech and Merck; and serving as a consultant or on advisory boards for AstraZeneca (institutional), Roche-Genentech (institutional), Guardant Health (institutional), Inivata, IO Biotech (institutional), Lilly, Merck, Novartis and Oncocyte (institutional)
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, David R. Gandara, MD, described the unique characteristics of the International Lung Cancer Congress which relied heavily on panel discussions, pro and con sessions, and case-based discussions instead of lectures.

“It’s purposely placed at the end of July, early August, so that we can basically have a think tank about what happened at ASCO and earlier meetings in the year,” Gandara, director of the thoracic oncology program at UC Davis Comprehensive Cancer Center and chief medical officer for the International Society of Liquid Biopsy, told Healio.